文献类型：期刊文献

英文题名：Prognostic value of FOXP3(+) regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

作者：Bai, Yuping[1];He, Tingting[1];Zhang, Liyan[2];Liu, Qianqian[1];Yang, Jing[1];Zhao, Ziru[1];Yang, Kehu[3];Zhang, Min[4]

第一作者：Bai, Yuping

通信作者：Zhang, M[1]

机构：[1]Gansu Univ Chinese Med, Sch Basic Med, Lanzhou, Peoples R China;[2]Hebei Cangzhou Hosp Integrated Tradit Chinese & W, Dept Pathol, Cangzhou, Peoples R China;[3]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China;[4]Gansu Prov Hosp, Dept Pathol, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Pathol, Lanzhou, Peoples R China.

年份：2022

卷号：12

期号：9

外文期刊名：BMJ OPEN

收录：;Scopus(收录号：2-s2.0-85138140775);WOS:【SCI-EXPANDED(收录号:WOS:000852862800039)】；

基金：This work was supported by the National Natural Science Foundation of China (grant number 81860059), the International Cooperation Exchange Project of Gansu Province (grant number 18YF1WA046) and the CAS 'Light of West China' Program.

语种：英文

外文关键词：lymphoma; immunology; haematology

摘要：Objectives We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3(+)) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results. Design Systematic review and meta-analysis. Data sources We searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021. Eligibility criteria We included studies that analysed the prognostic significance of FOXP3(+) Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis. Data extraction and synthesis We extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value. Results Fourteen eligible studies were identified. FOXP3(+) Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3(+) Treg expression (p(interaction)<0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3(+) Tregs was associated with better OS in all populations and in Asians when FOXP3(+) Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42). Conclusions Approaches to measuring FOXP3(+) Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3(+) Tregs in DLBCL. FOXP3(+) Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3(+) Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.